share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Biodexa Pharmaceuticals | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/02 05:22

Moomoo AI 已提取核心信息

Biodexa Pharmaceuticals announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024, following the resignation of Forvis Mazars LLP on October 25, 2024. The change was initiated after Forvis Mazars's notice of intent to resign, followed by a tender process evaluating both commercial terms and expertise of potential candidates.The reports from Forvis Mazars for fiscal years 2022 and 2023 contained no adverse opinions, except for a modification regarding the company's ability to continue as a going concern. During these periods and through October 25, 2024, there were no disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.The company confirmed that prior to the appointment, there were no consultations with PKF Littlejohn regarding accounting principles, audit opinions, or financial reporting matters. The transition process complies with SEC reporting requirements, with Forvis Mazars providing a letter to the SEC confirming these disclosures.
Biodexa Pharmaceuticals announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024, following the resignation of Forvis Mazars LLP on October 25, 2024. The change was initiated after Forvis Mazars's notice of intent to resign, followed by a tender process evaluating both commercial terms and expertise of potential candidates.The reports from Forvis Mazars for fiscal years 2022 and 2023 contained no adverse opinions, except for a modification regarding the company's ability to continue as a going concern. During these periods and through October 25, 2024, there were no disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.The company confirmed that prior to the appointment, there were no consultations with PKF Littlejohn regarding accounting principles, audit opinions, or financial reporting matters. The transition process complies with SEC reporting requirements, with Forvis Mazars providing a letter to the SEC confirming these disclosures.
Biodexa制药公司宣布任命PKF Littlejohn LLP为其新的独立注册公共会计师事务所，任命自2024年10月31日起生效，此前Forvis Mazars LLP于2024年10月25日辞职。此变更是在Forvis Mazars通知辞职意向后发起的，随后进行了评估潜在候选人的商业条款和专业能力的招标过程。Forvis Mazars在2022和2023财政年度的报告中没有提出任何不利意见，唯一的修改是关于公司持续经营能力的事项。在这些时期，直到2024年10月25日，双方在会计原则、实践、财务报表披露或审计程序上没有发生任何意见分歧。公司确认，在任命之前，没有与PKF Littlejohn进行关于会计原则、审计意见或财务报告事项的咨询。过渡过程符合SEC的报告要求，Forvis Mazars已向SEC提供了一封确认这些披露的信件。
Biodexa制药公司宣布任命PKF Littlejohn LLP为其新的独立注册公共会计师事务所，任命自2024年10月31日起生效，此前Forvis Mazars LLP于2024年10月25日辞职。此变更是在Forvis Mazars通知辞职意向后发起的，随后进行了评估潜在候选人的商业条款和专业能力的招标过程。Forvis Mazars在2022和2023财政年度的报告中没有提出任何不利意见，唯一的修改是关于公司持续经营能力的事项。在这些时期，直到2024年10月25日，双方在会计原则、实践、财务报表披露或审计程序上没有发生任何意见分歧。公司确认，在任命之前，没有与PKF Littlejohn进行关于会计原则、审计意见或财务报告事项的咨询。过渡过程符合SEC的报告要求，Forvis Mazars已向SEC提供了一封确认这些披露的信件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日